N2-aroylanthranilamide inhibitors of human factor Xa

Journal of Medicinal Chemistry

Volumn 43, Issue 5, 2000, Pages 873-882

  Yee, Ying K ^a   Tebbe, Anne Louise ^a   Linebarger, Jared H ^a   Beight, Douglas W ^a   Craft, Trelia J ^a   Gifford Moore, Donetta ^a   Goodson Jr , Theodore ^a   Herron, David K ^a   Klimkowski, Valentine J ^a   Kyle, Jeffrey A ^a   Sawyer, J Scott ^a   Smith, Gerald F ^a   Tinsley, Jennifer M ^a   Towner, Richard D ^a   Weir, Leonard ^a   Wiley, Michael R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBENZAMIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG CONFORMATION; DRUG POTENCY; HUMAN; MOLECULAR MODEL; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANTICOAGULANTS; BENZAMIDES; BINDING SITES; ENZYME INHIBITORS; FACTOR XA; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0034624694     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990327e     Document Type: Article

References (25)

1. The principle that inhibitors of fXa can produce anticoagulant effects in blood and can produce preclinical antithrombotic effects has been demostrated from studies of potent natural fXa inhibitors from the leech and the tick. (a) Vlasuk, G. P. Structural and Functional Characterization of Tick Anticoagulant Peptide (TAP): A Potent and Selective Inhibitor of Blood Coagulation Factor Xa. Thromb. Haemostasis 1993, 70, 212-216.
2. (b) Vlasuk, G. P.; Ramjit, D.; Fujita, T.; Dunwiddie, C. T.; Nutt, E. M.; Smith D. E.; Shebuski, R. J. Comparison of the In Vivo Anticoagulant Properties of Standard Heparin and the Highly Selective Factor Xa Inhibitors Antistatin and Tick Anticoagulant Peptide (TAP) in a Rabbit Model of Venous Thrombosis. Thromb. Haemostasis 1991, 65, 257-262.
3. (c) Schaffer, L. W.; Davidson, J. T.; Vlasuk, G. P.; Dunwiddie, C. T.; Siegl, P. K. S. Selective Factor Xa Inhibition by Recombinant Antistasin Prevents Vascular Graft Thrombosis in Baboons. Arterioscl. Thromb. 1992, 12, 879-885.
4. Small organic molecules which reversibly inhibit fXa have also been shown to produce anticoagulant activity in plasma and antithrombotic activity in animal models. (a) Hara, T.; Yokoyama, A.; Ishihara, H.; Yokoyama, Y.; Nagahara, T.; Iwamoto, M. DX-9065a, A New Synthetic, Potent Anticoagulant And Selective Inhibitor Of Factor Xa. Thromb. Haemostasis 1994, 71, 314-319.
5. (b) Herbert, J. M.; Bernat, A.; Dol, F.; Herault, J. P.; Crepon, B.; Lormeau, J. C. DX-9065a, A Novel, Synthetic Selective And Orally Active Inhibitor Of Factor Xa: In-Vitro And In-Vivo Studies. J. Pharmacol. Exp. Ther. 1996, 276, 1030-1038.
6. (c) Taniuchi, Y.; Sakai, Y.; Hisamichi, H.; Kayama, M.; Mano, Y.; Sato, K.; Hirayama, F.; Koshio, H.; Matsumoto, Y.; Kawasaki, T. Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa. Thromb. Haemostasis 1998, 79, 543-548.
7. Reviews: (a) Vacca, J. P. Thrombosis and Coagulation. Annu. Rep. Med. Chem. 1996, 33, 81-90.
8. (b) Al-Obeidi, F.; Ostrem, J. A. Factor Xa Inhibitors by Classical and Combinatorial Chemistry. Drug Discov. Today 1998, 3, 223-231.
9. (c) Sanderson, P. E. J. Small, Noncovalent Serine Protease Inhibitors. Med. Res. Rev. 1999, 19, 179-197.
10. Herron, D. K.; Goodson, T., Jr.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel, D.; Masters, J. J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood, B. J.; Towner, R D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa. J. Med. Chem. 2000, 43, 859-872.
11. Heck, R. F.; Ziegler, C. B. Palladium-catalyzed vinylic substitution with highly activated aryl halides. J. Org. Chem. 1978, 43, 2941-2946.
12. Manhas, M. S.; Amin, S. G.; Rao, V. V. Heterocyclic Compounds; IX. A Facile Synthesis Of Methaqualone And Analogues. Synthesis 1977, 309-310.
13. Zentmyer, D. T.; Wagner, E. C. The So-Called Acylanthranils (3,1,4-Benzoxazones). I. Preparation; Reactions With Water, Ammonia, And Aniline; Structure. J. Org. Chem. 1949, 14, 967-981.
14. Pavlidis, V. H.; Perry, P. J. The Synthesis Of A Novel Series Of Substituted 2-Phenyl-4H-3,1-Benzoxazin-4-ones. Synth. Commun. 1994, 24, 533-548.
15. Cram, D. J. Preorganization -From Solvents To Spherands. Angew Chem. Int. Ed. Engl. 1986, 25, 1039-1057.
16. Kollman, P. A. The Nature Of The Drug-Receptor Bond. In Burgers Medicinal Chemistry, 4th ed.; Wolff, M. E., Ed.; pp 322, 319.
17. Wiley, M. R.; Weir, L. C.; Briggs, S.; Bryan, N.; Buben, J.; Campbell, C.; Chirgadze, N. Y.; Conrad, R. C.; Craft, T. J.; Ficorilli, J. V.; Franciskovich, J. B.; Froelich, L. L.; Gifford-Moore, D. S.; Goodson, T., Jr.; Herron, D. K.; Klimkowski, V. J.; Kurz, K. D.; Kyle, J. A.; Masters, J. J.; Ratz, A. M.; Milot, G.; Shuman, R. T.; Smith, T.; Smith, G. F.; Tebbe, A. L.; Tinsley, J. M.; Towner, R. D.; Wilson, A.; Yee, Y. K. Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity. J. Med. Chem. 2000, 43, 883-899.
18. (a) Sall, D. J.; Bastian, J. A.; Briggs, S. L.; Buben, J. A.; Chirgadze, N. Y.; Clawson, D. K.; Denny, M. L.; Giera, D. D.; Gifford-Moore, D. S.; Harper, R. W.; Hauser, K. L.; Klimkowski, V. J.; Kohn, T. J.; Lin, H.; McCowan, J. R.; Palkowitz, A. D.; Smith, G. F.; Takeuchi, K.; Thrasher, K. J.; Tinsley, J. M.; Utterback, B. G.; Yan, S. B.; Zhang, M. Dibasic Benzo[b]thiophene Derivatives As A Novel Class Of Active Site-Directed Thrombin Inhibitors. J. Med. Chem. 1997, 40, 3489-3493.
19. (b) Smith, G. F.; Shuman, R. T.; Craft, T. J.; Gifford, D. S.; Kurz, K. D.; Jones, N. D.; Chirgadze, N.; Hermann, R. B.; Coffman, W. J.; Sandusky, G. E.; Roberts, E.; Jackson, C. V. A Family of Arginal Thrombin Inhibitors Related to Efegatran. Semin. Thromb. Hemostasis 1996, 22, 173-183.
20. Smith, G. F.; Gifford-Moore, D. S.; Craft T. J.; Chirgadze, N.; Ruterbories, K. J.; Lindstrom, T. D.; Satterwhite, J. H. Efegatran: A New Cardiovascular Anticoagulant. In New Anticoagulants for the Cardiovascular Patient; Pifarre, R., Ed.; Hanley & Belfus, Inc.: Philadelphia, 1997; pp 265-300.
21. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park C. H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of Human Des(1-45) Factor Xa at 2.2 Å Resolution J. Mol. Biol. 1993, 232, 947-966.
22. Molecular Simulations Inc., 9685 Scranton Rd., San Diego, CA 92121.
23. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
24. Henderson, P. J. F. A Linear Equation that Describes the Steady-State Kinetics of Enzymes and Subcellular Particles Interacting with Tightly Bound Inhibitors. Biochem, J. 1972, 127, 321-333.
25. Bieth, J. G. Pathophysiological Interpretation of Kinetic Constants of Protease Inhibitors. Bull. Eur. Physiopath. Resp. 1980, 16 (Suppl.), 183-195.